Skip to main content

Table 1 Summary of baseline characteristics

From: Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Characteristic Masitinib treatment (n= 26) Placebo (n= 8) P value
Age (years) 72 ± 12 78 ± 11 0.167
Gender (male/female) 11 (42%)/15 (58%) 2 (25%)/6 (75%) 0.444
Time since diagnosis (years) 1.7 ± 1.1 1.8 ± 0.8 0.320
ADAS-Cog (0 to 70) 18.8 ± 6.7 25.6 ± 12.1 0.161
MMSE (0 to 30) 19.1 ± 3.9 18.0 ± 4.4 0.650
CDR (1/2) 21 (81%)/5 (19%) 6 (75%)/2 (25%) 1.000
ADCS-ADL (0 to 70) 47.1 ± 11.2 45.9 ± 18.0 0.850
Concomitant Alzheimer's treatment   
   Cholinesterase inhibitors 26 (100%) 8 (100%) 0.180
   Memantine 4 (15%) 2 (25%) 0.610
  1. Data presented as mean ± standard deviation or number (%). ADAS-Cog, Alzheimer's Disease Assessment Scale - cognitive subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study Activities of Daily Living; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination.